À Saclay, l’incubateur de pointe de Servier cherche à attirer les start-up @La Tribune
La Tribune highlights our biotech company GEG-Tech, whose research laboratory is located in Saclay. The article notably reveals a technological partnership with Servier, France’s second-largest pharmaceutical group. GEG-Tech, a specialist in genetic engineering, is implementing its technology to strengthen the company’s drug screening and therapeutic innovation. The company announced an acceleration of its growth earlier […]
Retinal gene therapy: Visual cycle restored in blind mice
Press Release January 20th, 2025 Retinal gene therapy: Visual cycle restored in blind mice University of California, Irvine and GEG Tech announce results paving the way for high-precision gene therapy Over the last few years, the field of gene editing witnessed a tremendous acceleration as new therapies were approved and treatment strategies started to make […]
Release of new mRNA vectors for prime & base editing
GEG Tech launches a series of collaborations with leading research institutions to enable high-precision gene therapy based on genome editing GEG Tech announces the release of a new mRNA vector technology, designed to deliver novel prime and base editing systems. Leading research institutions in the field of genome editing, including the Broad Institute of MIT […]
We moved our Lab facility at Spartners by Servier and Biolabs
Very proud and excited to join this beautiful lab which is at the forefront of technology, in the middle of the burgeoning Paris-Saclay scientific ecosystem. With great collaborative projects on the horizon ! What better way to start a new GEG-Tech chapter!
Innovative Nanoparticles for ex vivo and in vivo Genome Editing
Innovative Nanoparticles to deliver mRNA for Vaccination
European Society of Gene and Cell Therapy ESGCT 30th Annual Congress, Brussels
Nicolas Grandchamp will be at the European Society of Gene and Cell Therapy ESGCT 30th Annual Congress, October 24-27 2023, Brussels. He will take advantage of this congress to present our latest results concerning the use of our property mRNA delivery platforms in genome editing.
GEG Tech and EPFL signed a collaborative research agreement
Brisken Lab, EPFL, and GEG Tech have established a collaboration in the field of breast cancer. Breast cancer affects one women in twelve during her lifetime and is now the cancer the most widely in the world (WHO 2021). The design of new therapeutic strategies against breast cancer is a huge challenge and represents a […]
World Vaccine Congress Europe, Barcelonna
Happy to announce the presence of Nicolas Grandchamp at the World Vaccine Congress Europe, October 17-19, 2023, Barcelona. He will take advantage of this congress to present our latest results concerning the use of our property mRNA delivery platforms in vaccination.
ISCT 2023, Paris
We are pleased to announce the presence of our CSO, Nicolas Grandchamp, PhD at the ISCT congress in Paris, from May 31 to June 3.
